Stable agonist of P2 receptors 2-methylthio-ATP and selective antagonists of P2X and P2Y receptors PPADS and reactive blue-2 were used for evaluation of the role of P2 receptors in positive contractile reaction of atrial and ventricular myocardium in rats. PPADS significantly moderated the effects of 2-methylthio-ATP in 14-, 21-, and 56-day-old rat pups, but potentiated them in 100-day-old rats. Under conditions of reactive blue-2 treatment, the positive effect of the agonist was preserved in the atria and ventricles in all age groups and was age-dependent.
We studied the effect of neuropeptide Y in concentrations of 10(-10)-10(-6) M on myocardial contractility of rats at the age of 7, 21, and 100 days. Studying the isometric contraction of myocardial strips showed that neuropeptide Y decreases the force of myocardial contraction in 7-day-old rat pups. Exogenous neuropeptide Y produced a biphasic effect in 21-day-old rats, which was manifested in the increase and subsequent decrease in myocardial contractility. Neuropeptide Y had little effect on myocardial contractility of 100-day-old animals.
Experiments with selective agonists and antagonists of purinoceptors allowed us to evaluate the subtype of P2X receptors. We showed that the myocardium of 14- 100-day-old rats contains functionally active P2X1 receptors. These receptors are involved in the realization of the positive inotropic effect of the atria and ventricles. Selective P2X1 receptor agonist beta,gamma-methylene-ATP induced a dose-dependent increase in the strength of atrial and ventricular contractions. P2X1 receptor antagonist TNP-ATP abolished the effect of the agonist in rats of all age groups.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.